The Management of Patients With Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis (IPF), the most common form of fibrosing idiopathic interstitial pneumonia, is an inexorably progressive disease with a 5-year survival of ~20%. In the last decade, our understanding of disease pathobiology has increased significantly and this has inevitably impacted on the approach to treatment. Indeed, the paradigm shift from a chronic inflammatory disorder to a primarily fibrotic one coupled with a more precise disease definition and redefined diagnostic criteria have resulted in a massive increase in the number of clinical trials evaluating novel candidate drugs. Most of these trials, however, have been negative, probably because of the multitude and redundancy of cell types, growth factors and profibrotic pathways involved in disease pathogenesis. As a consequence, until recently IPF has lacked effective therapies. Finally, in 2014, two large phase 3 clinical trials have provided robust evidence that pirfenidone, a compound with anti-fibrotic, anti-oxidant and anti-inflammatory properties, and nintedanib, a tyrosine kinase inhibitor with selectivity for vascular endothelial growth factor, platelet-derived growth factor and fibroblast growth factor receptors are able to slow down functional decline and disease progression with an acceptable safety profile. While this is a major achievement, neither pirfenidone nor nintedanib cures IPF and most patients continue to experience disease progression and/or exacerbation despite treatment. Therefore, in recent years increasingly more attention has been paid to preservation of quality of life and, in the advanced phase of the disease, palliation of symptoms. Lung transplantation, the only curative treatment, remains a viable option for only a minority of highly selected patients. The unmet medical need in IPF remains high, and more efficacious and better tolerated drugs are urgently needed. However, a truly effective therapeutic approach should also address quality of life and highly prevalent concomitant conditions and complications of IPF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654 · cited 3×
“More recently, two compounds pleiotropic in their mechanisms of action—pirfenidone and nintedanib—have been approved for the treatment of IPF based on their ability to slow down the pace of functional decline and disease progression in phase 3 clinical trials (9, 10).”
BackgroundMethodA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975 · cited 3×
“More recently, two compounds pleiotropic in their mechanisms of action—pirfenidone and nintedanib—have been approved for the treatment of IPF based on their ability to slow down the pace of functional decline and disease progression in phase 3 clinical trials (9, 10).”
BackgroundSpruit, M. A., Singh, S. J., Garvey, C., ZuWallack, R., Nici, L., Rochester, C., Hill, K., Holland, A. E., Lareau, S. C., Man, W. D.-C., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201309-1634st · Cited by 3,938
Richeldi, L., Collard, H. R., & Jones, M. G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30866-8 · Cited by 2,020
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
Collard, H. R., Ryerson, C. J., Corte, T. J., Jenkins, G., Kondoh, Y., Lederer, D. J., Lee, J. S., Maher, T. M., Wells, A. U., Antoniou, K. M., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201604-0801ci · Cited by 1,444 · cited 4×
“In a post-hoc subgroup analysis of pooled data from the INPULSIS trials (n = 1,061), Raghu and colleagues demonstrated that the rate of decline in FVC in patients with possible UIP on high-resolution CT (HRCT) [i.e., reticular abnormality and traction bronchiectasis in the absence of features inconsistent with usual i…”
BackgroundInfluentialWeill, D., Benden, C., Corris, P. A., Dark, J. H., Davis, R. D., Keshavjee, S., Lederer, D. J., Mulligan, M. J., Patterson, G. A., Singer, L. G., et al. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.06.014 · Cited by 1,329
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056 · cited 1×
“Nintedanib, previously known by its development code BIBF 1120, is an intracellular inhibitor of the tyrosine kinases vascular endothelial growth factor receptor (VEGFR) 1-3, fibroblast growth factor receptor (FGFR) 1-3, and platelet-derived growth factor receptor (PDGFR) a and b (31).”
BackgroundMoeller, A., Ask, K., Warburton, D., Gauldie, J., & Kolb, M. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.08.011 · Cited by 1,007
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005 · cited 1×
“By inhibiting VEGFR, FGFR, and PDGFR, nintedanib interferes with a number of processes that have been implicated in the pathogenesis of IPF, namely proliferation and migration of primary human lung fibroblasts, fibroblast to myofibroblast transformation, and TGFβ-stimulated secretion and deposition of collagen by prim…”
BackgroundAcute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622 · cited 1×
“Indeed, while the preferred time interval has been every 3 months, this may result in “missing events” in the case of patients who progress and die within this timeframewithout documentation of a significant decline of their FVC (111).”
BackgroundConte, E., Gili, E., Fagone, E., Fruciano, M., Iemmolo, M., & Vancheri, C. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.014 · Cited by 368 · cited 1×
“While its exact mechanism of action remains to be elucidated, pirfenidone’s biological effects are believed to occur mainly through suppression of tumor necrosis factor (TNF)-α, an early mediator of inflammation (14), and mediators in the transforming growth factor (TGF)-β pathway, such as the cytoplasmic Smad protein…”
BackgroundNathan, S. D., Albera, C., Bradford, W. Z., Costabel, U., Glaspole, I., Glassberg, M. K., Kardatzke, D. R., Daigl, M., Kirchgaessler, K.-U., Lancaster, L. H., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30326-5 · Cited by 335 · cited 1×
“Pooled analyses of ASCEND and CAPACITY trials and metaanalyses, which included also data from the SP2 and SP3 Japanese trials, confirmed that pirfenidone treatment reduced significant the risk of mortality compared with placebo over 120 weeks (21).”
MethodEfficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS
Costabel, U., Inoue, Y., Richeldi, L., Collard, H. R., Tschoepe, I., Stowasser, S., & Azuma, A. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201503-0562oc · Cited by 280
Dyspnea and pain share emotion-related brain network
von Leupoldt, A., Sommer, T., Kegat, S., Baumann, H. J., Klose, H., Dahme, B., & Büchel, C. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.06.015 · Cited by 257 · cited 1×
“The mechanisms behind dyspnea are not fully understood but neuroimaging studies have shown how dyspnea and pain activate common areas in the brain and share a cerebral network (100).”
BackgroundTzouvelekis, A., Paspaliaris, V., Koliakos, G., Ntolios, P., Bouros, E., Oikonomou, A., Zissimopoulos, A., Boussios, N., Dardzinski, B., Gritzalis, D., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-171 · Cited by 255 · cited 1×
“In a small cohort of patients with IPF (n = 14), Tzouvelekis and colleagues have shown that endobronchial infusion of autologous adipose derived stem cells was not associated with serious adverse events (69).”
BackgroundKreuter, M., Swigris, J., Pittrow, D., Geier, S., Klotsche, J., Prasse, A., Wirtz, H., Koschel, D., Andreas, S., Claussen, M., et al. (2017) · Respiratory Research · doi:10.1186/s12931-017-0621-y · Cited by 210 · cited 1×
“Dyspnea is strongly associated with reduced quality of life (97, 98) and has been shown to correlate with a worse prognosis (99).”
BackgroundKahloon, R. A., Xue, J., Bhargava, A., Csizmadia, E., Otterbein, L., Kass, D. J., Bon, J., Soejima, M., Levesque, M. C., Lindell, K. O., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201203-0506oc · Cited by 190 · cited 1×
“Autoantibody-Targeted Treatment Recent evidence suggests that immune dysregulation may contribute to IPF progression and that treatments that reduce autoantibodies may be beneficial in a significant minority of patients (63).”
BackgroundEffect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria
Raghu, G., Wells, A. U., Nicholson, A. G., Richeldi, L., Flaherty, K. R., Le Maulf, F., Stowasser, S., Schlenker-Herceg, R., & Hansell, D. M. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201602-0402oc · Cited by 180
Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis
Russell, A.-M., Adamali, H., Molyneaux, P. L., Lukey, P. T., Marshall, R. P., Renzoni, E. A., Wells, A. U., & Maher, T. M. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201511-2152oc · Cited by 178 · cited 1×
“Recently, Russell and colleagues have shown that unsupervised daily home spirometry is a feasible and clinically informative tool for monitoring disease behavior in patients with IPF (112).”
BackgroundFundoplication after lung transplantation prevents the allograft dysfunction associated with reflux
Hartwig, M. G., Anderson, D. J., Onaitis, M. W., Reddy, S., Snyder, L. D., Lin, S. S., & Davis, R. D. (2011) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2011.04.035 · Cited by 155 · cited 3×
“In addition, GER, which is highly prevalent in patients with IPF (80) and often complicates lung transplantation, is strongly associated with the development of BOS (81) and its presence should be carefully evaluated both pre- and post-transplantation (77).”
BackgroundLancaster, L., Albera, C., Bradford, W. Z., Costabel, U., du Bois, R. M., Fagan, E. A., Fishman, R. S., Glaspole, I., Glassberg, M. K., King, T. E., et al. (2016) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2015-000105 · Cited by 132
Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis
Donahoe, M., Valentine, V. G., Chien, N., Gibson, K. F., Raval, J. S., Saul, M., Xue, J., Zhang, Y., & Duncan, S. R. (2015) · PLOS ONE · doi:10.1371/journal.pone.0127771 · Cited by 125
Maher, T. M., Molina-Molina, M., Russell, A.-M., Bonella, F., Jouneau, S., Ripamonti, E., Axmann, J., & Vancheri, C. (2017) · BMC Pulmonary Medicine · doi:10.1186/s12890-017-0468-5 · Cited by 108 · cited 1×
“Maher and colleagues have recently reported that ∼40% of patients with confirmed IPF across Europe do not receive antifibrotic treatment (109).”
BackgroundSelf-citation
Cited by
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development
Spagnolo, P., Kropski, J. A., Jones, M. G., Lee, J. S., Rossi, G., Karampitsakos, T., Maher, T. M., Tzouvelekis, A., & Ryerson, C. J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107798 · Cited by 636
Self-citationIdiopathic Pulmonary Fibrosis: An Update on Pathogenesis
Mei, Q., Liu, Z., Zuo, H., Yang, Z., & Qu, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.797292 · Cited by 360
Herrmann, F. E., Hesslinger, C., Wollin, L., & Nickolaus, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.838449 · Cited by 137
Idiopathic Pulmonary Fibrosis: Where do We Stand and How Far to Go?
Singh, V., Ulasov, I., Gupta, S., Singh, A., Roy, V. K., & Kharwar, R. K. (2024) · Discovery Medicine · doi:10.24976/discov.med.202436180.3 · Cited by 17
Metadata
- Authors
- Spagnolo, P., Tzouvelekis, A., & Bonella, F.
- Venue
- Frontiers in Medicine
- Publisher
- Frontiers Media SA
- Published
- 2018-07-02
- Volume
- 5
- Pages
- 148-148
- ISSN
- 2296-858X (ISSN-L)
- OpenAlex
- W2800035714
- Cited by
- 72
- References
- 26
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.